Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

[Effects of trimetazidine therapy on left ventricular function after percutaneous coronary intervention].

Xu XH, Zhang WJ, Zhou YJ, Zhou ZM, Ma HY, Hu B, Kang YP, Luo FF.

Zhonghua Xin Xue Guan Bing Za Zhi. 2013 Mar;41(3):205-9. Chinese.

PMID:
23879944
2.

Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention.

Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G.

Am J Cardiovasc Drugs. 2007;7(2):143-50.

PMID:
17503885
3.

Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.

Bonello L, Sbragia P, Amabile N, Com O, Pierre SV, Levy S, Paganelli F.

Heart. 2007 Jun;93(6):703-7. Epub 2007 May 8.

4.

[Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study].

Chen YD, Zhao LK, Tian F, Du ZM, Jiang H, Wei M.

Zhonghua Nei Ke Za Zhi. 2010 Jun;49(6):473-6. Chinese.

PMID:
20979731
5.
6.
7.

[Effect of urapidil on heart function and ventricular systolic synchrony in acute myocardial infarction patients with no-reflow phenomenon after percutaneous coronary intervention].

Chen JL, Fu XH, Jiang YF, Fan WZ, Gu XS, Liu JJ, Geng W.

Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 Apr;20(4):197-9. Chinese.

8.

Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris.

Shlyakhto EV, Almazov VV, Nifontov EM, Vakhrameyeva IV, Rudomanov OG, Zakharov DV, Kazarin VV, Vakhrameyeva NV.

Am J Cardiovasc Drugs. 2002;2(2):119-24.

PMID:
14727987
9.

The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.

Li R, Tang X, Jing Q, Wang Q, Yang M, Han X, Zhao J, Yu X.

Am J Emerg Med. 2017 Nov;35(11):1657-1661. doi: 10.1016/j.ajem.2017.05.024. Epub 2017 May 23.

PMID:
28587952
10.
11.
12.
13.

[Influence of intracoronary administration of anisodamine on no-reflow, ventricular function and systolic synchrony in acute myocardial infarction patients undergoing percutaneous coronary intervention].

Fan WZ, Fu XH, Jiang YF, Gu XS, Wu WL, Li SQ, Liu J, Xue L, Wei YY, Hao GZ.

Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Oct;35(10):908-13. Chinese.

PMID:
18206037
14.

Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan.

Qarawani D, Cohen A, Nahir M, Hasin Y.

Int J Cardiol. 2013 Sep 20;168(1):237-42. doi: 10.1016/j.ijcard.2012.09.088. Epub 2012 Oct 11.

PMID:
23063476
15.

[Effect of left ventricular ejection fraction on clinical long-term follow-up outcomes in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].

Wang CH, Xie XJ, Fang Q, Zhang SY, Fang ZJ, Jiang XF, Xie HZ, Liu ZY, Shen ZJ.

Zhonghua Yi Xue Za Zhi. 2011 Jan 25;91(4):265-8. Chinese.

PMID:
21418873
16.
17.

Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.

Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM.

Eur Heart J. 2004 Oct;25(20):1814-21.

PMID:
15474696
18.

Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.

Gordin J, Haider A, Swaminathan RV, Kim LK, Minutello RM, Bergman G, Wong SC, Feldman DN.

Am J Cardiol. 2012 Nov 15;110(10):1397-404. doi: 10.1016/j.amjcard.2012.06.052. Epub 2012 Aug 2.

PMID:
22858186
19.

Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes.

Nageh T, Sherwood RA, Harris BM, Thomas MR.

Catheter Cardiovasc Interv. 2002 Jan;55(1):37-42.

PMID:
11793493
20.

Supplemental Content

Support Center